Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07132918 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HEARTS Trial for Thoracic Cancers

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 7 of 11 entries
  2. Eligibility criteria expanded, about 21 wordsv6
  3. Re-verified, no change to tracked fieldsv5
  4. Start date changed from estimate of Oct 2025 to Oct 8, 2025v4
  5. Start date: Sep 2025 to Oct 2025v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Wisconsin, Madison
304 trials monitored
See 21 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,078 trials monitored
See 172 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
and 1 more disease
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires
Trial Details
NCT Number NCT07132918
Lead Sponsor University of Wisconsin, Madison
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
Related terms Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Thymoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov